THIS WEBSITE IS FOR BUSINESS & INDUSTRY PARTNERS. FOR CONSUMER PRODUCTS VISIT :  BLIS Probiotics >

CONTACT US
CONTACT US

THE PREBIOTIC THAT

FLIPS A SWITCH

BLIS SynBoost™ is a patented synbiotic platform pairing Streptococcus salivarius BLIS K12™ and BLIS M18™ with raffinose — a prebiotic that activates the strains’ natural defence at the genetic level.

Enquire Now

SAME STRAINS, ENGINEERED FOR MORE

Proven Strains

Built on 160+ published studies and 70+ clinical trials across BLIS K12™ and BLIS M18™. 

More potent action

Up to 2,596x lantibiotic upregulation in vitro – demonstrated across both strains – activated through the prebiotic raffinose. 

Engineered synergy

Prebiotic and probiotic activate one another — a synbiotic system, not just two ingredients combined.

BUILT ON PUBLISHED SCIENCE

The synbiotic mechanism was characterised by Harold et al. (2024), Applied Microbiology 4:1320–1334. Raffinose upregulates lantibiotic gene expression across both BLIS strains, broadens the antimicrobial spectrum, and enlarges inhibition zones against key oral and ENT pathogens.

StrainGeneUpregulation with RaffinoseWhat it means
BLIS K12™ SalA up to 2,596-fold Broader antimicrobial spectrum
BLIS K12™ SalB up to 136-fold Greater potency vs. S. pyogenes
BLIS M18™ SalA up to 60-fold Stronger action vs. cariogenic bacteria
BLIS M18™ SalB up to 1,218-fold Greater potency vs. S. mutans
95%
reduction in tonsillitis incidence in children
BLIS K12™ · Di Pierro et al. 2014
81%
reduction in caries in preschoolers
BLIS M18™ · Kiselnikova & Toma 2022
73%
reduction in gingivitis, PMA index
BLIS M18™ · Kiselnikova & Toma 2022

BLIS SynBoost™ inherits the published evidence base of its component strains — 160+ studies · 70+ clinical trials trials.

Meet the Line-Up

Three SKUs. Two products. One platform.

BLIS SynBoost™ launches across two products and three dose tiers — purpose-built for the three highest-demand applications in oral and respiratory health.

1
500M CFU

BLIS SynBoost™ Oral 500

Fresh breath, every day.

Read the spec
2
750M CFU

BLIS SynBoost™ Oral 750

Fresh breath + dental health.

Read the spec
3
500M CFU

BLIS SynBoost™ Immunity 500

ENT & respiratory immunity.

Read the spec

Powered by BLIS K12™ + BLIS M18™ + Raffinose

Fresh breath, every day.

The daily-use tier of the BLIS SynBoost™ Oral product. Built for fresh breath claims and daily-routine oral wellness positioning. Pairs the two most clinically studied oral probiotic strains with the raffinose activation mechanism, at 500M CFU EOSL.

  • Reduces volatile sulfur compounds (VSCs) — the microbial source of bad breath
  • Maintains a balanced oral microbiome between dental visits
  • Supports overall oral wellness for daily-use consumer routines
Daily dose
500M CFU EOSL
Claim territory
Fresh breath; balanced oral microbiome
Target consumer
Adults investing in daily oral wellness routines
Formats
Lozenge, sachet, chewable, gum

Powered by BLIS K12™ + BLIS M18™ + Raffinose

Fresh breath. Plus the dental story.

The premium tier of BLIS SynBoost™ Oral. Same patented synbiotic combination at a higher 750M CFU EOSL dose, designed to unlock both fresh breath and dental health claim territory. Built on BLIS M18™'s published evidence base in caries reduction and gum health.

  • Helps maintain teeth and gum health alongside good oral hygiene
  • Targets cariogenic bacteria, including S. mutans, with greater antimicrobial potency
  • Supports a balanced oral microbiome and helps maintain fresh breath
Daily dose
750M CFU EOSL
Claim territory
Fresh breath + teeth and gum health
Target consumer
Premium oral wellness; proactive dental support
Formats
Lozenge, sachet, chewable, gum

Powered by BLIS K12™ + Raffinose

Synbiotic immunity, activated in the mouth.

The immunity SKU of the BLIS SynBoost™ platform. Pairs the world's most clinically studied oral probiotic — BLIS K12™, with 40+ trials including 20+ in children — with raffinose at 500M CFU EOSL. Built for parents, families and immunity-conscious adults.

  • Targets ENT pathogens including S. pyogenes — the bacteria behind strep throat
  • Colonises the oral cavity — the first physical barrier against airborne pathogens
  • Supports immune resilience during high-risk periods (winter, travel, run-down)
Daily dose
500M CFU EOSL
Claim territory
ENT and upper respiratory immune support
Target consumer
Parents, families, immunity-conscious adults
Formats
Lozenge, sachet, chewable, gum
Talk to our team

Have a project in mind?

Send us the details and we'll come back with the right strain, the supporting science, and a plan to get you moving.

Henry Sung

Global Key Account Manager ENQUIRE NOW